Rosing J, Tans G
Department of Biochemistry, Maastricht University, The Netherlands.
Thromb Haemost. 1997 Jul;78(1):427-33.
Blood coagulation factor V plays an important role in the regulation of thrombin formation. Activation of factor V by traces of activated coagulation factors (thrombin, factor Xa or meizothrombin) yields factor Va, the non-enzymatic cofactor of the prothrombinase complex. Since factor Va accelerates prothrombin activation under physiological conditions more than 10(4)-fold it is not surprising that down-regulation of factor Va cofactor activity by the protein C pathway is a very effective way for maintaining the hemostatic balance. In this paper we have reviewed the present status of structural knowledge of factor V and Va, the molecular changes in factor V that occur during factor V activation, the function of factor Va in prothrombin activation and the molecular mechanism of inactivation of factor Va by APC. Although considerable insight in the structure-function relationship of factor V and Va has been achieved, the study of mutated factor V molecules obtained by recombinant DNA technology will undoubtedly resolve remaining questions. The latter is illustrated by the fact that the discovery of factor VaLeiden has significantly contributed to our present knowledge on the regulation of the cofactor activity of factor Va via the protein C pathway. It appears that modulation of the activity of APC by protein S and factor Xa will strongly affect the in vivo activity of this pathway. Factor V not only plays an important role in the regulation of the activity of the prothrombinase complex but also acts as cofactor in APC-mediated inactivation of factor VIIIa. This gives rise to a rather intricate mechanism of regulation of thrombin formation by APC that thus far has been mainly studied in model systems containing purified proteins. Thus, extensive studies in plasma will be required in order to get more insight in the in vivo regulation of thrombin formation via the protein C pathway.
血液凝固因子V在凝血酶形成的调节中起重要作用。痕量活化凝血因子(凝血酶、因子Xa或中间凝血酶)激活因子V产生因子Va,即凝血酶原酶复合物的非酶辅因子。由于因子Va在生理条件下加速凝血酶原激活的作用超过10^4倍,因此蛋白C途径下调因子Va辅因子活性是维持止血平衡的一种非常有效的方式也就不足为奇了。在本文中,我们综述了因子V和Va的结构知识现状、因子V激活过程中发生的分子变化、因子Va在凝血酶原激活中的功能以及活化蛋白C(APC)使因子Va失活的分子机制。尽管对因子V和Va的结构-功能关系已经有了相当深入的了解,但通过重组DNA技术获得的突变因子V分子的研究无疑将解决剩余的问题。因子VaLeiden的发现对我们目前关于通过蛋白C途径调节因子Va辅因子活性的认识有显著贡献,这一事实就说明了后者。似乎蛋白S和因子Xa对APC活性的调节将强烈影响该途径的体内活性。因子V不仅在凝血酶原酶复合物活性的调节中起重要作用,而且在APC介导的因子VIIIa失活中作为辅因子发挥作用。这导致了APC调节凝血酶形成的机制相当复杂,迄今为止主要在含有纯化蛋白质的模型系统中进行研究。因此,需要在血浆中进行广泛研究,以便更深入地了解通过蛋白C途径对凝血酶形成的体内调节。